Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Rutgeerts

Showing results (11-20 of 320) with videos related to

Pageof 32
Sort By:
Expert Opinion on Biological Therapy|March 5, 2013
Certolizumab pegol in the treatment of Crohn's diseaseMarc Ferrante, Séverine Vermeire, Paul Rutgeerts
Postgraduate Medical Journal|February 19, 2014
Republished: Recent advances: personalised use of current Crohn's disease therapeutic optionsSéverine Vermeire, Marc Ferrante, Paul Rutgeerts
Food and Nutrition Bulletin|October 5, 2002
Stable isotopes and 13CO2 breath tests for investigating gastrointestinal functionsYvo Ghoos, Benny Geypens, Paul Rutgeerts
F1000 Medicine Reports|December 21, 2010
Vaccination and infection prevention in inflammatory bowel diseaseSeverine Vermeire, Gert Van Assche, Paul Rutgeerts
Gut|March 21, 2007
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?Paul Rutgeerts, Severine Vermeire, Gert Van Assche
European Journal of Pharmacology|October 20, 2009
Infliximab therapy for patients with inflammatory bowel disease: 10 years onGert Van Assche, Séverine Vermeire, Paul Rutgeerts
Current Drug Targets|March 10, 2010
Mucosal healing and anti TNFs in IBDGert van Assche, Séverine Vermeire, Paul Rutgeerts
World Journal of Gastroenterology|September 24, 2008
Treatment of severe steroid refractory ulcerative colitisGert Van Assche, Séverine Vermeire, Paul Rutgeerts
Current Gastroenterology Reports|November 14, 2008
Optimizing treatment of inflammatory bowel diseases with biologic agentsGert Van Assche, Séverine Vermeire, Paul Rutgeerts
Current Opinion in Gastroenterology|June 1, 2012
Classification of inflammatory bowel disease: the old and the newSeverine Vermeire, Gert Van Assche, Paul Rutgeerts
Pageof 32

Showing results (11-20 of 320) with videos related to

Sort By:
Pageof 32
Expert Opinion on Biological Therapy|March 5, 2013
Certolizumab pegol in the treatment of Crohn's diseaseMarc Ferrante, Séverine Vermeire, Paul Rutgeerts
Postgraduate Medical Journal|February 19, 2014
Republished: Recent advances: personalised use of current Crohn's disease therapeutic optionsSéverine Vermeire, Marc Ferrante, Paul Rutgeerts
Food and Nutrition Bulletin|October 5, 2002
Stable isotopes and 13CO2 breath tests for investigating gastrointestinal functionsYvo Ghoos, Benny Geypens, Paul Rutgeerts
F1000 Medicine Reports|December 21, 2010
Vaccination and infection prevention in inflammatory bowel diseaseSeverine Vermeire, Gert Van Assche, Paul Rutgeerts
Gut|March 21, 2007
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?Paul Rutgeerts, Severine Vermeire, Gert Van Assche
European Journal of Pharmacology|October 20, 2009
Infliximab therapy for patients with inflammatory bowel disease: 10 years onGert Van Assche, Séverine Vermeire, Paul Rutgeerts
Current Drug Targets|March 10, 2010
Mucosal healing and anti TNFs in IBDGert van Assche, Séverine Vermeire, Paul Rutgeerts
World Journal of Gastroenterology|September 24, 2008
Treatment of severe steroid refractory ulcerative colitisGert Van Assche, Séverine Vermeire, Paul Rutgeerts
Current Gastroenterology Reports|November 14, 2008
Optimizing treatment of inflammatory bowel diseases with biologic agentsGert Van Assche, Séverine Vermeire, Paul Rutgeerts
Current Opinion in Gastroenterology|June 1, 2012
Classification of inflammatory bowel disease: the old and the newSeverine Vermeire, Gert Van Assche, Paul Rutgeerts
Pageof 32